---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-183073"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2025-08-19T23:59:59+00:00"
generated_at: "2026-05-17T11:23:30.766068+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rein Therapeutics gets UK MHRA nod for Phase 2 IPF trial of LTI-03

## Summary
- UK MHRA authorized Phase 2 'RENEW' trial of LTI-03 for idiopathic pulmonary fibrosis (IPF).
- Trial will enroll up to 120 patients globally; two dose groups vs placebo over 24 weeks.
- Primary endpoint: safety/tolerability; secondary: lung function and imaging-based fibrosis measures.
- Patient recruitment in UK to begin soon; initial data expected in 2026.
- LTI-03 is first-in-class, designed to target fibrosis and protect lung regeneration; IPF median survival is 3-5 years.

## SEC filing metadata
- accession: 0001193125-25-183073
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2025-08-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312525183073/0001193125-25-183073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312525183073/d938122d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-183073
- JSON: https://secwatch.observer/filing/0001193125-25-183073.json
- Plain text: https://secwatch.observer/filing/0001193125-25-183073.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.